E-Cigarettes for Smoking Cessation
The single largest controversy in cessation. The evidence is strong in one direction and the guidelines genuinely split.
Evidence supporting e-cigarettes as cessation aids
- Cochrane living review (2024 update, R-013): high-certainty evidence that nicotine e-cigarettes increase quit rates compared with NRT; moderate-certainty evidence versus behavioural support or no support. This upgraded earlier (moderate) certainty ratings.
- Hajek et al., NEJM 2019 (R-005): in a UK stop-smoking service, e-cigarette users achieved roughly double the 1-year abstinence of NRT users (18.0% vs 9.9%).
- NICE NG209: clinicians may offer nicotine-containing e-cigarettes to people interested in using them to quit, with advice to stop smoking completely.
Evidence against / limitations
- Long-term safety is unknown. E-cigarettes are a relatively new product class; decades-long outcomes do not exist. Non-nicotine constituents (flavourings, aerosol byproducts) are under active study.
- WHO (2024): does not recommend e-cigarettes as cessation aids, citing insufficient evidence of safety and effectiveness at population level; notes industry involvement in the market.
- USPSTF (2021): I statement — evidence insufficient to assess the balance of benefits and harms; directs clinicians to interventions with proven effectiveness.
- Youth uptake concern: non-smoking young people who vape are at higher risk of later cigarette smoking in observational studies — a public-health harm independent of any cessation benefit.
- Dual use is common and its net effect is debated (see dual-use).
Guideline positions (as published)
| Body | Position |
|---|---|
| Cochrane (evidence body) | High-certainty evidence of efficacy vs NRT |
| NICE NG209 (UK) | May be offered as a cessation aid |
| WHO 2024 | Not recommended as cessation aid |
| USPSTF 2021 (US) | Evidence insufficient (I) |
What is known vs uncertain
- Known: nicotine e-cigarettes outperform NRT in randomized trials for quitting; they are not harmless; they are inappropriate for non-smokers, especially youth.
- Uncertain: long-term health effects; net population impact; optimal role relative to approved medications.
Platform position
The platform treats e-cigarettes as experimental-adjacent but trial-supported — stronger than "unproven", weaker than approved medications, and never for non-smokers. Community reports of vaping-assisted quits are recorded in the experience database without endorsement.